Quinoline Derivative MC1626, a Putative GCN5 Histone Acetyltransferase (HAT) Inhibitor, Exhibits HAT-Independent Activity against Toxoplasma gondii | Zendy

Aaron T. Smith | Zendy; Meredith R. Livingston | Zendy; Antonello Mai | Zendy; Patrizia Filetici | Zendy; Sherry F. Queener | Zendy; William J. Sullivan | Zendy

Open Access

Quinoline Derivative MC1626, a Putative GCN5 Histone Acetyltransferase (HAT) Inhibitor, Exhibits HAT-Independent Activity against Toxoplasma gondii

Author(s) -

Aaron T. Smith,

Meredith R. Livingston,

Antonello Mai,

Patrizia Filetici,

Sherry F. Queener,

William J. Sullivan

Publication year - 2006

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01256-06

Subject(s) - apicoplast , toxoplasma gondii , quinoline , histone acetyltransferase , acetyltransferase , biology , organelle , plastid , derivative (finance) , acetylation , microbiology and biotechnology , biochemistry , chemistry , genetics , chloroplast , organic chemistry , gene , financial economics , antibody , economics

We report that quinoline derivative MC1626, first described as an inhibitor of the histone acetyltransferase (HAT) GCN5, is active against the protozoan parasiteToxoplasma gondii in vitro. However, MC1626 does not inhibitToxoplasma GCN5 HATs or reduce HAT-mediated activity; rather, this quinoline may target the plastid organelle called the apicoplast.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research